<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01409603</url>
  </required_header>
  <id_info>
    <org_study_id>150-CL-039</org_study_id>
    <secondary_id>2009-015762-64</secondary_id>
    <nct_id>NCT01409603</nct_id>
  </id_info>
  <brief_title>To Evaluate Whether Naproxen and Darexaban (YM150) Interact in Their Effects</brief_title>
  <official_title>A Phase I, Open-Label, Randomized 3-Period Crossover Study in Healthy Male Subjects to Evaluate the Pharmacodynamic Interactions Between YM150 on Naproxen at Steady-State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate whether naproxen and darexaban which have
      different effects on blood coagulation influence each other in their effects. Also it will be
      investigated whether the blood levels of either drug are influenced by the presence of the
      other drug. In addition, the safety and tolerability of each drug and the combination of the
      drugs will be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of pharmacodynamics of naproxen</measure>
    <time_frame>Baseline and 3 hours after multiple dosing (darexaban: 6 days, naproxen: 4 days) of darexaban, naproxen, or a combination of the two</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacodynamics of darexaban</measure>
    <time_frame>Baseline and 3 hours after multiple dosing (darexaban: 6 days, naproxen: 4 days) of darexaban, naproxen, or a combination of the two</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of darexaban assessed by plasma concentration</measure>
    <time_frame>Plasma samples are taken until 24 hours after six days of dosing of darexaban, or the combination with naproxen</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of naproxen assessed by plasma concentration</measure>
    <time_frame>Plasma samples are taken until 12 hours after four days of dosing of naproxen, or the combination with darexaban</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of safety and tolerability through assessment of vital signs, Electrocardiogram (ECG), clinical safety laboratory and adverse events</measure>
    <time_frame>6 days (for treatment periods with darexaban) or 4 days. (naproxen alone)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Pharmacodynamic Interaction</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>darexaban, wash-out, naproxen, wash-out, combination therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>darexaban, wash-out, combination therapy, wash-out, naproxen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>naproxen, wash-out, darexaban, wash-out, combination therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>naproxen, wash-out, combination therapy, wash-out, darexaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination therapy, wash-out, naproxen, wash-out, darexaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination therapy, wash-out, darexaban, wash-out, naproxen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darexaban</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment arm A</arm_group_label>
    <arm_group_label>Treatment arm B</arm_group_label>
    <arm_group_label>Treatment arm C</arm_group_label>
    <arm_group_label>Treatment arm D</arm_group_label>
    <arm_group_label>Treatment arm E</arm_group_label>
    <arm_group_label>Treatment arm F</arm_group_label>
    <other_name>YM150</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment arm A</arm_group_label>
    <arm_group_label>Treatment arm B</arm_group_label>
    <arm_group_label>Treatment arm C</arm_group_label>
    <arm_group_label>Treatment arm D</arm_group_label>
    <arm_group_label>Treatment arm E</arm_group_label>
    <arm_group_label>Treatment arm F</arm_group_label>
    <other_name>Naprosyne</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) between 18.5-30.0 kg/m2

          -  Male subjects must be non-fertile, i.e. surgically sterilized or must practice an
             adequate contraceptive method to prevent pregnancies

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to darexaban or naproxen or any components of the
             formulation used

          -  A contra-indication for the use of naproxen

          -  Any of the liver function tests (i.e. ALT, AST and bilirubin) above the upper limit of
             normal at repeated measures

          -  Any clinically significant history of any other disease or disorder -
             gastrointestinal, cardiovascular, respiratory, renal, hepatic, neurological,
             dermatological, psychiatric or metabolic as judged by the medical investigator.

          -  Any clinically significant abnormality following the investigator's review of the
             pre-study physical examination, ECG and clinical laboratory tests

          -  Use of any prescribed or OTC (over-the-counter) drugs (including vitamins, natural and
             herbal remedies, e.g. St. John's wort) in the 2 weeks prior to admission to the
             Clinical Unit, except for occasional use of paracetamol (up to 3 g/day)

          -  Regular use of any inducer of liver metabolism (e.g. barbiturates, rifampicin) in the
             3 months prior to admission to the Clinical Unit

          -  Donation of blood or blood products within 3 months prior to admission to the Clinical
             Unit

          -  Any use of drugs of abuse, or smoking of more than 10 cigarettes (or equivalent) or
             more than 21 units (210 g) of alcohol per week within the 3 months prior to study

          -  Participation in any clinical study within 3 months or participation in more than 3
             clinical studies within 12 months, prior to the expected date of enrolment into the
             study, provided that the clinical study did not entail a biological compound with a
             long terminal half life
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>SGS Aster, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Aster</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=564</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2011</study_first_submitted>
  <study_first_submitted_qc>August 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2011</study_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacodynamics</keyword>
  <keyword>darexaban</keyword>
  <keyword>naproxen</keyword>
  <keyword>YM150</keyword>
  <keyword>Phase 1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Darexaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

